Literature DB >> 6206179

Molecular localization of human class II MT2 and MT3 determinants.

C K Hurley, R C Giles, G Nunez, R DeMars, L Nadler, R Winchester, P Stastny, J D Capra.   

Abstract

The specificities of the monoclonal antibodies I-LR2 and 109d6, which recognize MT2- and MT3-like serologic determinants, respectively, have been confirmed by panel testing. In addition, the relationships of these antibodies to other monoclonal antibodies and alloantisera have been studied by means of cell surface fluorescence, complement-dependent cytotoxicity and immunoprecipitation. Using these monoclonal antibodies, molecules encoded by the HLA-D region have been isolated and characterized by amino acid sequencing and peptide mapping. By these criteria, the major populations of molecules bearing MT2- and MT3-like determinants are indistinguishable from DR molecules.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206179      PMCID: PMC2187460          DOI: 10.1084/jem.160.2.472

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   17.579


  53 in total

1.  Association of PLT specificity of alloreactive lymphocyte clones with HLA-DR, MB and MT determinants.

Authors:  A Zeevi; C Scheffel; K Annen; G Bass; M Marrari; R J Duquesnoy
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

Review 2.  The genetic control of human Ia alloantigens: a three-loci model derived from the immunochemical analysis of 'supertypic' specificities.

Authors:  N Tanigaki; R Tosi
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

3.  Human B cell alloantigens: expression of MB and MT determinants.

Authors:  M L Markert; P Cresswell
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

4.  Two-dimensional gel analysis of the polypeptides precipitated by a polymorphic HLA-DR1,2,w6 monoclonal antibody: evidence for a third locus.

Authors:  T A De Kretser; M J Crumpton; J G Bodmer; W F Bodmer
Journal:  Eur J Immunol       Date:  1982-07       Impact factor: 5.532

Review 5.  HLA-DR antigens: structure, separation of subpopulations, gene cloning and function.

Authors:  D A Shackelford; J F Kaufman; A J Korman; J L Strominger
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

6.  The human HLA-DR antigens are encoded by multiple beta-chain loci.

Authors:  C K Hurley; G Nunez; R Winchester; O J Finn; R Levy; J D Capra
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

7.  Direct evidence of homology between human DC-1 antigen and murine I-A molecules.

Authors:  M R Bono; J L Strominger
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

8.  Alpha and beta chains of SB and DR antigens are structurally distinct.

Authors:  C K Hurley; S Shaw; L Nadler; S Schlossman; J D Capra
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

9.  Serologic identification of the human secondary B cell antigens. Correlations between function, genetics, and structure.

Authors:  S Shaw; R DeMars; S F Schlossman; P L Smith; L A Lampson; L M Nadler
Journal:  J Exp Med       Date:  1982-09-01       Impact factor: 14.307

10.  Biochemical characterization of a second family of human Ia molecules, HLA-DS, equivalent to murine I-A subregion molecules.

Authors:  S M Goyert; J E Shively; J Silver
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

View more
  15 in total

1.  Polymorphisms within the HLA-DRw6 haplotype. II. Protein charge heterogeneity reflects MLC subtyping of HLA-DRw6 homozygous cells.

Authors:  M L Bosch; A Termijtelen; R Gerrets; G M Schreuder; R E Bontrop; M J Giphart
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  Recognition of class II molecules by human T cells. I. Analysis of epitopes of DR and DQ molecules in a DRw11, DRw52, DQw3 haplotype.

Authors:  L K Myers; E J Ball; G Nuñez; P Stastny
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  Molecular characterization of MT3 antigens by two-dimensional gel electrophoresis, NH2-terminal amino acid sequence analysis, and southern blot analysis.

Authors:  R Sorrentino; J Lillie; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  DQ alpha and beta RFLP reveals the composition of the DQ molecule recognized by T-cell clones.

Authors:  S Rosenshine; I Cascino; A Zeevi; R J Duquesnoy; M Trucco
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

5.  Allostimulating cells in man. Quantitative variation in the expression of HLA-DR and HLA-DQ molecules influences T-cell activation.

Authors:  G Nuñez; E J Ball; L K Myers; P Stastny
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

6.  Evolutionary and genetic implications of sequence variation in two nonallelic HLA-DR beta-chain cDNA sequences.

Authors:  J M Curtsinger; J M Hilden; J S Cairns; F H Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

7.  Structural organization of the DR subregion of the human major histocompatibility complex.

Authors:  T Spies; R Sorrentino; J M Boss; K Okada; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

8.  Allelic polymorphism and transassociation of molecules encoded by the HLA-DQ subregion.

Authors:  R C Giles; R DeMars; C C Chang; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  An antiviral T-cell clone defines a functional supertypic specificity shared by different HLA-DR molecules from DR2-short, DRw11, and DRw13 haplotypes.

Authors:  D Zeliszewski; G Sterkers; J Choppin; C Freidel; L Gebuhrer; H Betuel; J P Levy
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

10.  Nucleotide sequence of an HLA-DQ alpha chain derived from a DRw9 cell line: genetic and evolutionary implications.

Authors:  J Moriuchi; T Moriuchi; J Silver
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.